Biomarker: HSD17B1

Biomarker subtype: mRNA

Clinical application: prognosis(unfavorable)

Histology type: endometrial carcinoma

Country: Norway

Region: Hordaland

Followed up time : 9 years(mean, 7 years)

Cohort age: 84;91

Sample type : tissue

Clinical method: mRNA analyses(cDNA microarray.)/immunohistochemistry

Expression pattern : high mRNA level

Expression elevation: Enzyme levels were categorised in quartiles patients , each consisting of equal number of high levels were classified as all patients in the 2nd, 3rd and 4rd)

Statictics: cutoff<67;cutoff>67

Cohort age: 84;91

Description: In conclusion;HSD17B1 is a promising marker to predict EC prognosis.Immunohistochemical detection of this protein in ECs has low sensitivity and should be improved for future clinical applications.

Approved symbol: HSD17B1

Approved name: hydroxysteroid 17-beta dehydrogenase 1

Locus type: gene with protein product

HGNC ID: HGNC:5210

HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5210

Symbol status: Approved

Previous symbols: EDHB17 EDH17B2

Alias symbols: HSD17 MGC138140 SDR28C1

Alternative gene group name: SDR family

OMIM: 109684

Omim link: https://www.omim.org/entry/109684

NCBI name: 3292

NCBI link: https://www.ncbi.nlm.nih.gov/gene/3292

Summary: This gene encodes a member of the 17beta-hydroxysteroid dehydrogenase family of short-chain dehydrogenases/reductases. It has a dual function in estrogen activation and androgen inactivation and plays a major role in establishing the estrogen E2 concentration gradient between serum and peripheral tissues. The encoded protein catalyzes the last step in estrogen activation, using NADPH to convert estrogens E1 and E2 and androgens like 4-androstenedione, to testosterone. It has an N-terminal short-chain dehydrogenase domain with a cofactor binding site, and a narrow, hydrophobic C-terminal domain with a steroid substrate binding site. This gene is expressed primarily in the placenta and ovarian granulosa cells, and to a lesser extent, in the endometrium, adipose tissue, and prostate. Polymorphisms in this gene have been linked to breast and prostate cancer. A pseudogene of this gene has been identified. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2016]

Expression: Biased expression in placenta (RPKM 41.1), fat (RPKM 4.7) and 11 other tissues

NCBI gene expression https://www.ncbi.nlm.nih.gov/gene/3292#gene-expression

PDB ID: P14061

PDB link: https://www.ebi.ac.uk/pdbe/entry/search/index/?searchParams=%7B%22q_uniprot%22:%5B%7B%22value%22:%22(P14061)%22,%22condition1%22:%22AND%22,%22condition2%22:%22Contains%22%7D%5D,%22resultState%22:%7B%22tabIndex%22:0,%22paginationIndex%22:1,%22perPage%22:%2210%22,%22sortBy%22:%22Sort%20by%22%7D%7D

MF term ID: GO:1903924

MF term name: estradiol binding

Source description: TF|MIRNA

Term ID: MIRNA:hsa-miR-518c-3p

Term name: hsa-miR-518c-3p